Navigation Links
New link identified for bipolar disorder
Date:6/17/2010

Lithium has been established for more than 50 years as one of the most effective treatments for manic depression, clinically termed bipolar disorder.

However, scientists have never been entirely sure exactly why it is beneficial.

Now, new research from Cardiff University scientists suggests a possible mechanism for why Lithium works, opening the door for better understanding of the illness and potentially more effective treatments.

Laboratory studies with cells have shown that an enzyme known as prolyl oligopeptidase (PO) controls a set of genes that determine sensitivity to lithium. Among these genes is ImpA2, which like PO activity itself, has been associated with differences in some bipolar patients. These results reveal a new mechanistic link that could explain these changes in these patients.

Professor Adrian Harwood of Cardiff School of Biosciences, who led the research, said: "We still cannot say definitively how lithium can help stabilise bipolar disorder. However, our research has uncovered a new cell signalling process with links to bipolar disorder.

"This introduces a new mechanism and more candidate genes whose study could lead to greater understanding of the causes of bipolar disorder, better diagnostic tests and new types of drugs that are more effective and have fewer side effects than Lithium does at present."

The research, funded by the Wellcome Trust, is published in the international journal PLoS ONE.


'/>"/>

Contact: Stephen Rouse
Rouses@cardiff.ac.uk
44-292-087-5596
Cardiff University
Source:Eurekalert

Page: 1

Related biology news :

1. Key mechanism identified in metastatic breast cancer
2. Biological link between stress, anxiety and depression identified for the first time
3. New genetic risk factors for aneurysms identified by Yale-led team
4. Autism susceptibility genes identified
5. Structure of insulins docking point identified
6. Newly identified growth factor promotes stem cell growth, regeneration
7. Cell of origin identified for common type of breast cancer
8. Genetic risk factor identified for Parkinsons disease
9. Canine compulsive disorder gene identified
10. Canine compulsive disorder gene identified in dogs
11. Genetic causes identified for disturbances in lipid metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology: